Skip to main content

Table 1 Patient characteristics at the start of the run-in phase and patients with primary endpoints at the end of the 3-year trial phase

From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)

  All (SUP + IMM) Supportive Care (SUP) Supportive Care plus Immunosuppression (IMM)
(N = 70) (N = 32) (N = 38)
Patient characteristics:
 Female sex -% 17 13 21
 Smoker -% 19 19 18
 Age –yr 43.4 ± 13.6 48.2 ± 10.8 39.3 ± 14.5
 Body-mass index 28.0 ± 5.0 29.0 ± 4.8 27.3 ± 5.1
 Blood pressure- mmHg
  Systolic 131 ± 14 135 ± 16 127 ± 12
  Diastolic 82 ± 11 86 ± 11 79 ± 10
 Serum creatinine -mg/dl 1.4 ± 0,5 1.5 ± 0.5 1.3 ± 0.5
 eGFR-ml/min/1.73m2 67 ± 28 61 ± 25 73 ± 30
 Creatinine clearance - ml/min 82 ± 34 (N = 60) 80 ± 30 (N = 28) 84 ± 37 (N = 32)
 Daily urinary protein excretion - g/day 2.3 ± 1.3 2.4 ± 1.3 2.2 ± 1.3
 Urinary protein-creatinine ratio - g/g 1.4 ± 0.8 (N = 60) 1.4 ± 0.8 (N = 28) 1.4 ± 0.8 (N = 32)
 Cholesterol - mg/dl 210 ± 44 (N = 67) 208 ± 37 (N = 29) 211 ± 48(N = 38)
Primary endpoints:
 Full clinical remissiona 8 2 6
 eGFR-loss ≥15 ml/min 23 11 12
 ESRDb 8 4 4
  1. aurinary protein-creatinine ratio < 0.2 g/g and an eGFR decrease of < 5 ml/min/1.73m2
  2. bend-stage renal disease